Galantamine Attenuates Aluminum Chloride-Induced Cytotoxicity and Modulates Tumor Necrosis Factor Expression in SH-SY5Y Cells
International Journal of Medical Toxicology and Forensic Medicine,
Vol. 16 (2026),
1 January 2026
,
Page 1-8
https://doi.org/10.22037/ijmtfm.v16.52729
Abstract
Background: Neuroinflammation and oxidative stress are central to Alzheimer's disease pathogenesis. Aluminum chloride (AlCl₃) is a neurotoxicant utilized to model these pathological features, whereas galantamine, a clinically approved therapeutic, exhibits secondary anti-inflammatory properties. To evaluate the protective efficacy of galantamine against AlCl₃-induced cytotoxicity and its modulatory impact on tumor necrosis factor (TNF) gene expression in human neuroblastoma cells.
Methods: SH-SY5Y cells were exposed to varying concentrations of AlCl₃ or galantamine for 24 hours. For combination treatments, cells were pretreated with galantamine prior to AlCl₃ exposure. Cellular viability was evaluated using the MTT assay, and relative TNF mRNA expression was quantified via RT-qPCR.
Results: High-dose AlCl₃ (500 µg/mL) significantly decreased cell viability to 65% and upregulated TNF expression by 2.3-fold (p<0.001). Pretreatment with galantamine (100 µg/mL) partially restored cell viability (88–95%) and significantly suppressed the AlCl₃-induced TNF overexpression to 0.36-fold of control levels (p<0.001).
Conclusion: Galantamine confers neuroprotection against metal-induced cellular injury by downregulating pro-inflammatory signaling cascades. These findings highlight its potential therapeutic utility in mitigating neuroinflammation-driven neurodegenerative processes beyond its primary cholinergic action.
- Alzheimer disease, Cholinesterase inhibitors, Neuroprotective agents, Cell survival, Inflammation
How to Cite
References
[1] Safiri S, Ghaffari Jolfayi A, Fazlollahi A, Morsali S, Sarkesh A, Daei Sorkhabi A, et al. Alzheimer’s disease: a comprehensive review of epidemiology, risk factors, symptoms diagnosis, management, caregiving, advanced treatments and associated challenges. Front Med 2024;11:1474043. [DOI: 10.3389/fmed.2024.1474043]
[2] Beera AM, Seethamraju SM, Nori LP. Alzheimer’s disease: perspective on therapeutic options and recent hallmarks in clinical research. Int J Pharm Res Allied Sci 2021;10:110–20. [DOI: 10.51847/ViC6sAGCyq]
[3] Chen Z-R, Huang J-B, Yang S-L, Hong F-F. Role of cholinergic signaling in Alzheimer’s disease. Molecules 2022;27:1816. [DOI: 10.3390/molecules27061816]
[4] Kaya ZB, Santiago-Padilla V, Lim M, Boschen SL, Atilla P, McLean PJ. Optimizing SH-SY5Y cell culture: exploring the beneficial effects of an alternative media supplement on cell proliferation and viability. Sci Rep 2024;14:4775. [DOI: 10.1038/s41598-024-55516-5]
[5] Shunan D, Yu M, Guan H, Zhou Y. Neuroprotective effect of Betalain against AlCl3-induced Alzheimer’s disease in Sprague Dawley Rats via putative modulation of oxidative stress and nuclear factor kappa B (NF-κB) signaling pathway. Biomed Pharmacother 2021;137:111369. [DOI: 10.1016/j.biopha.2021.111369]
[6] Anyanwu E, Nwachukwu J, Obasi K, Ekwueme P, Anyanwu C. Fisetin attenuates AlCl3-induced neurodegeneration by modulating oxidative stress and inflammatory cytokine release in adult albino wistar rats. Toxicol Reports 2024;13:101812. [DOI: 10.1016/j.toxrep.2024.101812]
[7] Service CCE, Lim AWY, Schneider L, Loy C. Galantamine for dementia due to Alzheimer’s disease and mild cognitive impairment. Cochrane Database Syst Rev 1996;2024. [DOI: 10.1002/14651858.CD001740.pub5]
[8] Sperling LE, Reis KP, Nicola F, Teixeira CE, Didó GG, Dos Santos MG, et al. Galantamine improves functional recovery and reduces lesion size in a rat model of spinal cord injury. Brain Res 2019;1724:146424. [DOI: 10.1016/j.brainres.2019.146424]
[9] Zaghloul N, Cohen NS, Ayasolla KR, Li H-L, Kurepa D, Ahmed MN. Galantamine ameliorates hyperoxia-induced brain injury in neonatal mice. Front Neurosci 2023;17:890015. [DOI: 10.3389/fnins.2023.890015]
[10] Mustafa Rizvi SH, Parveen A, Verma AK, Ahmad I, Arshad M, Mahdi AA. Aluminium induced endoplasmic reticulum stress mediated cell death in SH-SY5Y neuroblastoma cell line is independent of p53. PLoS One 2014;9:e98409. [DOI: 10.1371/journal.pone.0098409]
[11] Arias E, Alés E, Gabilan NH, Cano-Abad MF, Villarroya M, García AG, et al. Galantamine prevents apoptosis induced by β-amyloid and thapsigargin: involvement of nicotinic acetylcholine receptors. Neuropharmacology 2004;46:103–14. [DOI: 10.1016/S0028-3908(03)00317-4]
[12] Elboghdady AM, Shousha WG, Allayeh AK, Ramadan SS, Ewies EF, El-Ella AA, et al. In Vitro Cytotoxic Evaluation of Quercetin-Loaded Lecithin-Chitosan Nanoparticles against Colorectal Cancer. Egypt J Chem 2026;69:27–40. [DOI: 10.21608/ejchem.2025.433527.12527]
[13] PIRO O, BROZE GJ. Comparison of cell-surface TFPIα and β. J Thromb Haemost 2005;3:2677–83. [DOI: 10.1111/j.1538-7836.2005.01636.x]
[14] Kumar GA, Pravallika P, Thirumalai V, Bukke SPN, Rao PBB, Thalluri C, et al. Persicaria hydropiper attenuates oxidative stress and reactive oxygen species, and inhibits amyloid-β/tau in SH-SY5Y cell lines via multiple pathways of Alzheimer’s disease. J Alzheimer’s Dis 2026;110:821–36. [DOI: 10.1177/13872877261418555]
[15] Fu W-Y, Wang X, Ip NY. Targeting neuroinflammation as a therapeutic strategy for Alzheimer’s disease: mechanisms, drug candidates, and new opportunities. ACS Chem Neurosci 2018;10:872–9. [DOI: 10.1021/acschemneuro.8b00402]
[16] Fakhoury M. Inflammation in Alzheimer’s disease. Curr Alzheimer Res 2020;17:959–61. [DOI: 10.2174/156720501711210101110513]
[17] Calabrese EJ. Hormesis and medicine. Br J Clin Pharmacol 2008;66:594–617. [DOI: 10.1111/j.1365-2125.2008.03243.x]
[18] Mattson MP. Hormesis defined. Ageing Res Rev 2008;7:1–7. [DOI: 10.1016/j.arr.2007.08.007]
[19] Plantone D, Pardini M, Righi D, Manco C, Colombo BM, De Stefano N. The role of TNF-α in Alzheimer’s disease: a narrative review. Cells 2023;13:54. [DOI: 10.3390/cells13010054]
[20] Rizvi S, Parveen A, Ahmad I, Ahmad I, Verma A, Arshad M, et al. Aluminum Activates PERK-EIF2α Signaling and Inflammatory Proteins in Human Neuroblastoma SH-SY5Y Cells. Biol Trace Elem Res 2016;172:108. [DOI: 10.1007/s12011-015-0553-7]
[21] Plantone D, Pardini M, Righi D, Manco C, Colombo BM, De Stefano N. The Role of TNF-α in Alzheimer’s Disease: A Narrative Review. Cells 2023;13. [DOI: 10.3390/cells13010054]
[22] Li Q, Fang J, Yang M, Wu D, Zhang L, Zhang Y. Galantamine inhibits calpain–calcineurin signaling activated by beta-amyloid in human neuroblastoma SH-SY5Y cells. Neurosci Lett 2010;480:173–7. [DOI: 10.1016/j.neulet.2010.06.005]
[23] Decourt B, K Lahiri D, N Sabbagh M. Targeting tumor necrosis factor alpha for Alzheimer’s disease. Curr Alzheimer Res 2017;14:412–25. [DOI: 10.2174/1567205013666160930110551]
[24] Nafea M, Elharoun M, Abd-Alhaseeb MM, Helmy MW. Leflunomide abrogates neuroinflammatory changes in a rat model of Alzheimer’s disease: the role of TNF-α/NF-κB/IL-1β axis inhibition. Naunyn Schmiedebergs Arch Pharmacol 2023;396:485–98. [DOI: 10.1007/s00210-022-02322-3]
[25] Kenchappa PG, Karthik Y, Vijendra PD, Hallur RLS, Khandagale AS, Pandurangan AK, et al. In vitro evaluation of the neuroprotective potential of Olea dioica against Aβ peptide-induced toxicity in human neuroblastoma SH-SY5Y cells. Front Pharmacol 2023;14:1139606. [DOI: 10.3389/fphar.2023.1139606]
- Abstract Viewed: 7 times
- PDF Downloaded: 3 times